Corrigendum: Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma

Sibin Zhang[1†], Xu Xiao[1†], Yu Wang[2], Tianjun Song[3], Chenlong Li[1], Hongbo Bao[1], Qing Liu[1], Guiyin Sun[1], Xiaoyang Sun[1], Tianqi Su[1], Tianjiao Fu[1], Yujie Wang[1] and Peng Liang[1]*

[1]Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China, [2]Department of Esophageal Surgery, Harbin Medical University Cancer Hospital, Harbin, China, [3]Department of Medicine II, University Hospital LMU Munich, Munich, Germany

A Corrigendum on

Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma

by Zhang S, Xiao X, Wang Y, Song T, Li C, Bao H, Liu Q, Sun G, Sun X, Su T, Fu T, Wang Y and Liang P (2022). Front. Genet. 13:899125. doi: 10.3389/fgene.2022.899125

In the published article, there was an error in Figure 2 as published. The second ROC curve in Figure 2B and the second KM curve in Figure 2C are same with the first ROC curve in Figure 2B and the first KM curve in Figure 2C, respectively. The corrected Figure 2 appears below.

In the published article, there was an error in **Results**, *Immune-Related Signature and the Survival of Patients With Glioma*, **paragraph 1**. This sentence previously stated: "In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.93 and 0.90"

The corrected sentence appears below:

"In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.94 and 0.93"

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

FIGURE 2
Immune-related signature effectively predicts the prognosis of patients with glioma. **(A)** Risk score distribution, survival status and expression of 15 hub genes for glioma in low-risk and high-risk groups. **(B)** 1, 3 and 5-year ROC curve analyses. ROC, receiver operating characteristic. **(C)** K-M survival curve analyses.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.